Future Tech: Almost Here, Round-the-corner Future Technology Podcast

VistaGen Therapeutics is a clinical-stage biopharmaceutical company concentrating on developing new generation medicines for depression and other central nervous system (CNS) disorders. The lead CNS product candidate, AV-101, is a new generation antidepressant drug candidate in Phase 2 development. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat major depressive disorder (MDD), with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. In addition to the AV-101 programs, VistaStem, VistaGen’s wholly owned subsidiary, is focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage,